FDA Speeds Up Approvals for Lab Test Devices
Published Date: 5/1/2026
Notice
Summary
The FDA wants to make it easier for some medical devices used in toxicology tests by removing the need for a special pre-approval process. This change could speed up how these devices get to market and might save money for makers and users. The FDA is asking for your thoughts by June 30, 2026, before making a final decision.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
510(k) Exemption for Toxicology Tests
FDA intends to exempt certain Class II clinical toxicology test system devices from the 510(k) premarket notification when they are intended for Federal drug testing programs. If finalized, regulated industry will no longer need to submit 510(k) submissions for those listed devices, reducing the time and private costs businesses now spend preparing 510(k)s.
Exemptions Subject to Limits and Labeling
Even if exempted from 510(k), these devices remain subject to the general limitations in 21 CFR 862.9 and the proposed partial limitation that the test system be intended for employment and insurance testing and include labeling stating it is intended solely for employment and insurance testing. Manufacturers must still submit a 510(k) before marketing if a device exceeds those limitations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13492 — Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has confirmed that vasopressin in sodium chloride (0.9%, injection) wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can now get approved if they meet all the rules, helping patients and healthcare providers get more options. No changes in price or availability are expected right now, but more generics could be coming soon!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2026-08496 — Agency Information Collection Activities: Proposed Collection; Comment Request
SAMHSA is updating the annual report form for the PATH program, which helps states and territories support people transitioning from homelessness. This change affects all PATH grant recipients and aims to make reporting clearer and easier, without adding extra costs or time. Comments are open now, so stakeholders can share ideas before the January 31 deadline for submitting reports.
Next: 2026-08500 — Combined Notice of Filings #1
The Federal Energy Regulatory Commission got a bunch of new filings from energy companies like solar farms and power plants. These filings include status updates, tariff changes, and complaints that could affect energy rates and operations soon. If you’re involved in energy or just curious, keep an eye on deadlines for comments mostly due by mid-May 2026.